HXL's Principal Activity is
the research, development and commercialisation of technology for the genetic modification of crops, primarily to enhance their resistance to insects and fungal pathogens.
Share Price Activity
Last (Price)
Change
0.00
(0.00)
Bid / Ask
-
Volume
Volume (4w avg)
Turnover
Open
Day Range
-
VWAP
Prev Close
Last Trade
Performance
1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr)
-
vs ASX 200 (1yr)
+111.64%
Size
Market Cap
Excludes mandatory escrowed shares and foreign shares.
Hexima Limited (HXL) is a biotechnology company actively engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Hexima's lead drug candidate is the plant defensin, pezadeftide (formerly HXP124), which is being developed for treatment of fungal nail infections (onychomycosis). Hexima is conducting a phase IIb clinical trial at 15 sites in Australia and New Zealand. The trial has enrolled 117 patients with onychomycosis and seeks to identify the optimal course of therapy for pezadeftide.
Mr Nunn has more than 25 years' experience in the life science industry as an investor, independent director, research analyst and investment banker. Jake is currently an independent advisor to several life science companies and a venture advisor at New Enterprise Associates (NEA), where he was an investing partner from 2006 to 2018 focused on the biopharmaceutical and medical technology sectors. Jake has founded NEA's public market healthcare investing practice in 2006 and led NEA to become one of anchor investors in small-cap public biopharma special situations/PIPE investing over the last decade. Prior to NEA, Jake was Partner at MPM Capital, South San Francisco, California. Mr Nunn is a director of public companies Regulus Therapeutics Inc, Oventus Medical Ltd, Trevena Inc, and Addex Therapeutics Ltd. He was previously a director of several companies in the pharmaceutical sector including Dermira Inc. (acquired by Eli Lilly) and Hyperion Therapeutics (acquired by Horizon Pharma plc).
Mr Steven Michael Skala
Alternate Director
Mar 2020
Mr Steven Michael Skala
Alternate Director
Mr Skala is Vice Chairman, Australia of Deutsche Bank AG, a position he has held since 2004 and is Chairman of the Commonwealth Government's Clean Energy Finance Corporation. Among public companies, he is a former Chairman of Wilson Group Limited, the Island Food Company Limited and is a former Director of the Channel TEN Group of companies and Max Capital Group Limited. Between 1982 and 2004, he was a Partner of Australian law firms, Morris Fletcher & Cross (now Minter Ellison) and Arnold Bloch Leibler. Active beyond banking and commerce, Mr Skala is Chairman of the Heide Museum of Modern Art, Deputy Chairman of the General Sir John Monash Foundation, a Director of the Centre for Independent Studies and a Member of the International Council of the Museum of Modern Art (MoMA) in New York. He was previously Chairman of Film Australia Limited, Chairman of the Australian Centre for Contemporary Art, Vice President (Deputy Chairman) of The Walter & Eliza Hall Institute of Medical Research, a Director of the Australian Broadcasting Corporation and a Director of the Australian Ballet. He was appointed an Officer of the Order of Australia in January 2010 for service to the arts, education, business and commerce.
Mr Michael Douglas Aldridge
Chief Executive Officer,Managing Director
May 2019
Mr Michael Douglas Aldridge
Chief Executive Officer,Managing Director
Mr Aldridge most recently served as Senior Vice President, Corporate & Strategic Development, Codexis from October 2016 until August 2018. Prior to that, from January 2012 to September 2014, Mr. Aldridge served as Senior Vice President, Corporate Strategic Development Questcor Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company acquired by Mallinckrodt Pharmaceuticals in 2014. From May 2010 to September 2012, Mr. Aldridge served as Chief Executive Officer and a member of the board of directors Xenome Limited, a privately-held biopharmaceutical company headquartered in Australia. Between 2003 and 2009, Mr. Aldridge served as Chief Executive Officer and a member of the board of directors and a strategic consultant at Peplin, Inc., a publicly-traded drug development company acquired by LEO Pharma A/S in 2009. Prior to that, Mr. Aldridge held investment banking positions at various financial firms, including Wilson HTM Investment Group, Bear, Stearns & Co., Volpe, Brown, Whelan & Company and S.G. Warburg Group
Mr Scott Christian Robertson
Non-Executive Director
Nov 2018
Mr Scott Christian Robertson
Non-Executive Director
Mr Robertson is currently Chief Financial Officer at DiCE Molecules. Prior to DiCE Molecules, Mr Robertson served at DuPont where he was Business Development Director for DuPont Pioneer with responsibility for the business unit's crop genetics and precision agriculture M&A activity. He also held the position of portfolio manager with DuPont Ventures where he focused on strategic investment opportunities in production agriculture and the intersection of agriculture and downstream renewable technologies. Prior to joining DuPont, Mr Robertson was an investment professional at MPM Capital, a life sciencesdedicated venture capital fund, and previous to that a member of the Healthcare Investment Banking groups at Merrill Lynch & Co. and Thomas Weisel Partners.
Mr Justin Zhen Nan Yap
Non-Executive Director
Jul 2018
Mr Justin Zhen Nan Yap
Non-Executive Director
Mr Yap is a Non-Executive Director of CathRx Limited, an Australian medical device company commercialising cardiac electrophysiology catheters for the treatment of heart rhythm disorders. He is a Non-Executive Director of Wilhelm Integrated Solutions Pty Ltd, a leading supplier of integrated OR solutions to hospitals around Australia. Prior to this, he began his career in investment banking for Mosaic Risk Management Pty Ltd, a wholly owned subsidiary of Wilson HTM Limited specialising in derivatives risk management.
Dr Nicole Louise van der Weerden
Chief Operating Officer,Executive Director
Dec 2014
Dr Nicole Louise van der Weerden
Chief Operating Officer,Executive Director
Dr Weerden completed her PhD in Biochemistry at La Trobe University in 2007. Her PhD research on the antifungal properties and mechanism of action of plant defensins led to the award of a prestigious Victoria Fellowship in 2006. Since completing her PhD, Dr Weerden has worked for Hexima and has led the gene discovery program for the Pioneer partnership on control of fungal diseases in corn. She led the Hexima team that identified the clinical opportunities for plant antifungal molecules and discovered and developed pezadeftide (formerly HXP124) for treatment of onychomycosis. Dr Weerden is an inventor on nine patent applications
Professor Jonathan West
Non-Executive Director,Non-Executive Chairman
Nov 2005
Professor Jonathan West
Non-Executive Director,Non-Executive Chairman
Mr West was the founding Director of the Australian Innovation Research Centre. Prior to assuming that appointment, he taught for 18 years at the Harvard University Graduate School of Business Administration, where he was Associate Professor, founding Director of the Harvard University Life Sciences Initiative, and from 1998-1999 the Novartis Faculty Research Fellow. He has been Visiting Professor at Hitotsubashi University and the Nomura School of Advanced Management in Tokyo, Japan and Visiting Professor at the University de Paris IXDauphine, Sorbonne. Professor West was Chairman of the Asia Advisory Council of Bunge Ltd, one of the world's largest agribusiness processing and trading companies, and has served as an advisor to other major corporations and several Governments around the world, including in the life sciences field, DuPont, Roche, Novartis, Syngenta and the J.R. Simplot Company, along with the Governments of Singapore, Japan, Hong Kong and France. He was a member of the Scientific Advisory Board of the Novartis Agricultural Discovery Institute in La Jolla, California. In Australia, he has served on the Prime Minister's Science, Engineering, Innovation Council's Working Group on Science and Technology in China and India and in 2006 was 'Eminent Thinker in Residence' with the Premier of NSW. Professor West is Non-Executive Chairman of Gowing Bros Limited and Non-Executive Director of Boundary Bend Limited and the Hydration Pharmaceuticals Trust. Professor West has been a Director of the Company since 7 November 2005 and was appointed Non-Executive Chairman on 18 November 2014. He is a member of the Remuneration and Nomination Committee and Chairman of the Audit and Risk Management Committee.
Data supplied by Morningstar and accurate on Aug 18, 2021.
It's not possible to publish a real-time Top 20 Shareholder list.
Companies are not obliged to report this data (with the exception of Substantial
Shareholders above 5%). If a company chooses to publish the data,
it's usually once a year in their Annual Report.
All data is manually compiled so there might be a delay between the Annual Report
being published and the data appearing on Market Index (<7 days for ASX 300
and up to 30 days for micro-caps).
A substantial shareholder is a person or entity that owns 5% or more of
the voting shares in a company. Shares can be held through multiple
entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market.
When all “Last Notice” dates are identical, it suggests that no (or minimal)
change
has occurred since the most recent Annual Report.
Name
Last Notice
Total Shares
Shares Held (%)
Woobinda Nominees Pty Ltd and its associates
18/08/2021
14,939,353
11.40
Gowing Bros Ltd
18/08/2021
7,923,307
6.10
Dato Lim Sen Yap
18/08/2021
14,715,790
11.20
Woobinda Nominees Pty Limited
09/12/2021
15,126,853
9.06
Shareholders Buying
12 month transaction history compiled from ASX announcements.
Date
Name
Bought
Previous %
New %
09-12-21
Woobinda Nominees Pty Limited
467,500
11.20
9.06
Shareholders Selling
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
